We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Scripps Tumorgraft Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01726699
Recruitment Status : Completed
First Posted : November 15, 2012
Last Update Posted : April 3, 2015
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Study the genetic traits of cancerous tissues and to help improve cancer treatment by developing tumor models for studying new cancer drugs.

Condition or disease
Solid Tumor Malignancy or Hematologic Malignancy

Study Design

Study Type : Observational
Actual Enrollment : 11 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Scripps Tumorgraft Study
Study Start Date : November 2012
Primary Completion Date : July 2014
Study Completion Date : July 2014
Groups and Cohorts

Group/Cohort
Cancer Diagnosis


Outcome Measures

Primary Outcome Measures :
  1. Facilitate the development of individualized tumorgraft models for many different types of cancer. [ Time Frame: 3 years ]

Biospecimen Retention:   Samples With DNA
Blood and tissue samples

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adults with a solid tumor malignancy or a hematologic malignancy
Criteria

Inclusion Criteria:

  • Age 21 or over
  • diagnosis of a solid tumor malignancy, either resectable or metastatic or a hematologic malignancy
  • cognitively and emotionally able to give informed consent

Exclusion Criteria:

  • Under age 21
  • Not cognitively or emotionally able to give informed consent
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01726699


Locations
United States, California
Scripps Translational Science Institute
La Jolla, California, United States, 92037
Sponsors and Collaborators
Scripps Translational Science Institute
Investigators
Principal Investigator: Laura Goetz, MD Director, Applied Genetic Epidemiology
More Information

Responsible Party: Eric Topol, MD, Director, Applied Genetic Epidemiology, Scripps Translational Science Institute
ClinicalTrials.gov Identifier: NCT01726699     History of Changes
Other Study ID Numbers: 12-6011
First Posted: November 15, 2012    Key Record Dates
Last Update Posted: April 3, 2015
Last Verified: April 2015

Additional relevant MeSH terms:
Neoplasms